| Shirl Douglas George, MD | |
|
555 E Broadway Ave Ste 108, Jackson, WY 83001-8640 | |
| (307) 734-1313 | |
| (307) 734-0314 |
| Full Name | Shirl Douglas George |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 41 Years |
| Location | 555 E Broadway Ave Ste 108, Jackson, Wyoming |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043392863 | NPI | - | NPPES |
| 114060400 | Medicaid | WY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 6199A (Wyoming) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Johns Medical Center | Jackson, WY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Womens Health And Family Care Llc | 7315192556 | 4 |
News Archive
Researchers from Allina Health and the Minneapolis Heart Institute Foundation have presented on the results and implications of The Heart of New Ulm Project on heart disease risk factors at the American Heart Association Scientific Sessions in Chicago, Ill.
The U.S. Food and Drug Administration (FDA) approved a new once-a-month dose (150 mg) of Actonel (risedronate sodium) tablets for the treatment and prevention of postmenopausal osteoporosis. Actonel is approved to reduce the risk of fractures in postmenopausal women with osteoporosis.
A new paradigm to explain glaucoma is rapidly emerging, and it is generating brain-based treatment advances that may ultimately vanquish the disease known as the "sneak thief of sight." A review now available in Ophthalmology, the journal of the American Academy of Ophthalmology, reports that some top researchers no longer think of glaucoma solely as an eye disease.
The U.S. Food and Drug Administration (FDA) sent letters warning seven pharmacy operations that the claims they make about the safety and effectiveness of their so-called "bio-identical hormone replacement therapy," or "BHRT" products are unsupported by medical evidence, and are considered false and misleading by the agency.
Advantagene, Inc., a Massachusetts-based biopharmaceutical company, announced today that it reached an agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment (SPA) for a pivotal Phase 3 clinical trial of ProstAtak™, its lead agent for patients with newly diagnosed prostate cancer.
› Verified 4 days ago
| Entity Name | Womens Health & Family Care Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316282072 PECOS PAC ID: 7315192556 Enrollment ID: O20130219000531 |
News Archive
Researchers from Allina Health and the Minneapolis Heart Institute Foundation have presented on the results and implications of The Heart of New Ulm Project on heart disease risk factors at the American Heart Association Scientific Sessions in Chicago, Ill.
The U.S. Food and Drug Administration (FDA) approved a new once-a-month dose (150 mg) of Actonel (risedronate sodium) tablets for the treatment and prevention of postmenopausal osteoporosis. Actonel is approved to reduce the risk of fractures in postmenopausal women with osteoporosis.
A new paradigm to explain glaucoma is rapidly emerging, and it is generating brain-based treatment advances that may ultimately vanquish the disease known as the "sneak thief of sight." A review now available in Ophthalmology, the journal of the American Academy of Ophthalmology, reports that some top researchers no longer think of glaucoma solely as an eye disease.
The U.S. Food and Drug Administration (FDA) sent letters warning seven pharmacy operations that the claims they make about the safety and effectiveness of their so-called "bio-identical hormone replacement therapy," or "BHRT" products are unsupported by medical evidence, and are considered false and misleading by the agency.
Advantagene, Inc., a Massachusetts-based biopharmaceutical company, announced today that it reached an agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment (SPA) for a pivotal Phase 3 clinical trial of ProstAtak™, its lead agent for patients with newly diagnosed prostate cancer.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Shirl Douglas George, MD Po Box 14230, Jackson, WY 83002-4230 Ph: (307) 734-1313 | Shirl Douglas George, MD 555 E Broadway Ave Ste 108, Jackson, WY 83001-8640 Ph: (307) 734-1313 |
News Archive
Researchers from Allina Health and the Minneapolis Heart Institute Foundation have presented on the results and implications of The Heart of New Ulm Project on heart disease risk factors at the American Heart Association Scientific Sessions in Chicago, Ill.
The U.S. Food and Drug Administration (FDA) approved a new once-a-month dose (150 mg) of Actonel (risedronate sodium) tablets for the treatment and prevention of postmenopausal osteoporosis. Actonel is approved to reduce the risk of fractures in postmenopausal women with osteoporosis.
A new paradigm to explain glaucoma is rapidly emerging, and it is generating brain-based treatment advances that may ultimately vanquish the disease known as the "sneak thief of sight." A review now available in Ophthalmology, the journal of the American Academy of Ophthalmology, reports that some top researchers no longer think of glaucoma solely as an eye disease.
The U.S. Food and Drug Administration (FDA) sent letters warning seven pharmacy operations that the claims they make about the safety and effectiveness of their so-called "bio-identical hormone replacement therapy," or "BHRT" products are unsupported by medical evidence, and are considered false and misleading by the agency.
Advantagene, Inc., a Massachusetts-based biopharmaceutical company, announced today that it reached an agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment (SPA) for a pivotal Phase 3 clinical trial of ProstAtak™, its lead agent for patients with newly diagnosed prostate cancer.
› Verified 4 days ago
Dr. Henry Thomas Smith, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 230 East Broadway, Jackson, WY 83001 Phone: 307-733-1122 Fax: 307-734-9577 | |
Shannon Christine Roberts, MD FACOG Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 555 E Broadway Ave, Ste 108, Jackson, WY 83001 Phone: 307-734-1005 Fax: 307-734-1165 | |
Dr. Camille Stephanie Mellijor-figg, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 430 S Cache St, Jackson, WY 83001 Phone: 307-201-1489 | |
Maura Jean Lofaro, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 555 E Broadway Ave, Suite 108, Jackson, WY 83001 Phone: 307-734-1005 Fax: 307-734-1165 | |
Roger Malcom Brecheen, MD FACOG Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 555 E Broadway, Ste 201, Jackson, WY 83001 Phone: 307-733-8537 Fax: 307-733-0141 | |
Giovannina Anthony, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 555 E Broadway Ave Ste 108, Jackson, WY 83001 Phone: 307-734-1313 Fax: 307-734-0314 |